EviCure

EviCure is developing a novel extracellular vesicle (EV)--based platform technology for cancer treatment. EviCure leverages AI capabilities and sophisticated human cancer disease models for in-depth comparative analyses of various stem cell subpopulations and secreted EVs to achieve robust and specific anti-tumor effects against a wide range of solid tumors. In addition to their endogenous therapeutic effects, EviCure’s EVs can be used as vehicles for the targeted delivery of RNA-based therapies, peptides, and small therapeutic molecules. This combined approach generates EVs that target multiple oncogenic pathways associated with tumor growth, metastasis, and resistance to radiation and advanced treatments. EviCure has also developed a groundbreaking approach for the of scale up of EVs using artificial intelligence (AI) algorithms and biological sensors to produce EVs in a consistent and reproducible process maintaining their anti-tumor effects throughout the entire scale-up production. PL-Ex-1 is the first product on EviCure’s platform and is expected to become a leading EV treatment against lung cancer providing a safe, cost-effective, mutation-agnostic, and stage-independent treatment for different types of lung and other solid tumors.

EviCure has raised $700K in total funding across 3 rounds. The company is currently at the Seed stage. Key investors include Peregrine Ventures.

EviCure operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

EviCure is based in Rehovot, Israel, Center District.